在使用GLP-1受体激剂的患者中,使用mastopexy进行乳房植入物扩张:回顾性比较分析
1Mayanei HaYeshua Medical Centre, affiliated with the Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; The Dina Recanati School of Medicine Reichman University, Herzliya, Israel.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS
|October 28, 2025
概括
葡萄糖类-1 (GLP-1) 受体激活剂可能会增加乳腺手术并发症,患者表现出较高的伤口愈合问题和较低的营养标志物. 对于专门的患者管理,需要进一步的研究.
科学领域:
- 整形外科 整形外科 整形外科
- 内分泌学 在内分泌学.
- 外科手术的结果
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激动剂广泛用于体重管理.
- 尽管它们对手术结果的潜在影响,但它们对乳腺手术结果的影响仍未得到充分研究.
研究的目的:
- 为了比较GLP-1受体激动剂使用者和对照者之间的乳腺植入物与乳腺查的术后结果.
- 确定手术治疗和营养状况的潜在风险和差异.
主要方法:
- 30个GLP-1使用者和30个匹配的对照组的回顾性比较案例系列.
- 评估的结果包括并发症率,伤口愈合,感染,体重减轻和营养参数.
- 匹配标准包括年龄,体重指数和吸烟状态.
主要成果:
- GLP-1患者的整体并发症率数量上较高 (20%对10%),以及伤口愈合并发症 (13.3%对3.3%).
- 在GLP-1使用者中观察到显著的体重减轻 (7.8公斤与0.5公斤相比).
- GLP-1患者的血清白蛋白和前白蛋白水平较低,表明潜在的营养缺陷.
结论:
- 使用GLP-1受体激活剂的患者可能面临乳腺手术并发症的风险增加,特别是伤口愈合问题.
- 营养状况,以低专辑蛋白和前专辑蛋白为证据,可能是导致因素.
- 建议对这些接受乳腺手术的患者进行专业的术后管理.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.7K
03:55Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma
Published on: December 29, 2023
1.0K
相关概念视频
01:24Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
01:23Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575